HERON THERAPEUTICS, INC. /DE/

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
CINVANTI	approved	$21.8MQ2 2026	24	approved
ZYNRELEF KIT	approved	$11.1M*Q2 2026	21	approved
APONVIE	approved	$4.3MQ2 2026	24	approved
SUSTOL	approved	$0.5MQ2 2026	3	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (25)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT06109428	phase4	completed	2021-10-12	2022-03-29	Heron Therapeutics	A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE
NCT06109415	phase4	completed	2021-10-20	2022-07-18	Heron Therapeutics	A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.
NCT05109312	phase4	unknown	2021-10-12	2024-06-01	Heron Therapeutics	A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.
NCT02106494	phase3	completed	2014-03-01	2015-05-01	Heron Therapeutics	A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
NCT00343460	phase3	completed	2006-06-01	2008-09-01	Heron Therapeutics	APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

FDA applications (4)

Application

Approved

Type

Applicant

Products

NDA 216457

2022-09-16

NDA

HERON THERAPEUTICS INC

NDA 211988

2021-05-12

NDA

HERON THERAPEUTICS INC

NDA 209296

2017-11-09

NDA

HERON THERAPEUTICS INC

NDA 022445

2016-08-09

NDA

HERON THERAPEUTICS INC